Trial Profile
A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Foralumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Sponsors Light Chain Bioscience; NovImmune SA
- 09 Mar 2011 New trial record